1. VlachoJannis GJ, Dimitropoulos G, Alexopoulos D. Clopidogrel resistance: current aspects and future directions. Hellenic J Cardiol 2011; 52: 236–5.
2. DiNicolantonio JJ, Tomek A. Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial. Int J Cardiol 2013; 168: 4076–80.
3. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Amer Coll Cardiol 2013; 61: 723–7.
4. James S,  Budaj A, Aylward P et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function. Results from the PLATO. Circulation 2010; 122: 1056–67.
5. Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea? Thromb Haemost 2012; 108 (6): 1031–6.
6. Mustafa SJ, Morrison RR, Teng B, Pelleg A. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharmacol 2009; 193: 161–88.
7. Fernandez P, Jara C, Aguilera V et al. Adenosine A2A and A3 receptors are involved in the human endothelial progenitor cells migration. J Cardiovasc Pharmacol 2012; 59: 397–404.
8. Johnston-Cox HA, Yang D, Ravid K. Physiological implications of adenosine receptor-mediated platelet aggregation. J Cell Physiol 2011; 226: 46–51.
9. Barletta KE, Ley K, Mehrad B. Regulation of neutrophil function by adenosine. Arterioscler Thromb Vasc Biol 2012; 32: 856–64.
10. Csóka B, Németh ZH, Rosenberger P et al. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol 2010; 185: 542–50.
11. Belardinelli L, Shryock JC, Song Y et al. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J 1995; 9: 359–65.
12. Rankin AC, Brooks R, Ruskin JN, McGovern BA. Adenosine and the treatment of supraventricular tachycardia. Am J Med 1992; 92: 655–64.
13. Headrick JP, Lasley RD. Adenosine receptors and reperfusion injury of the heart. Handb Exp Pharmacol 2009; 193: 189–214.
14. Hausenloy DJ, Bøtker HE, Condorelli G et al. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2013; 98: 7–27.
15. Singh M, Shah T, Khosla K et al. Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Ther Adv Cardiovasc Dis 2012; 6: 101–14.
16. Seideman P, Sollevi A, Fredholm BB. Additive renal effects of indomethacin and dipyridamole in man. Br J Clin Pharmacol 1987; 23: 323–30.
17.  Strauer BE, Heidland UE, Heintzen MP, Schwartzkopff B. Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: impact on hemodynamic function and left ventricular performance. J Am Coll Cardiol 1996; 28: 1119–26.
18. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol 2013; 61: 723–7.
19. Armstrong A, Summers C, Ewart L et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther 2014; 19: 209–19.
20. Alexopoulos D, Moulias A, Koutsogiannis N et al. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study. Circ Cardiovasc Interv 2013; 6: 277–83.
21. Nylander S, Femia EA, Scavone M et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost 2013; 11: 1867–76.
22. Moser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol 1989; 256: C799–C806.
23. Van Giezen JJ, Sidaway J, Glaves P et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012; 17: 164–72.
24. Wang K, Zhou X, Huang Y et al. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost 2010; 104: 609–17.
25. Bonello L, Laine M, Kipson N et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014; 63: 872–7.
26. Torngren K, Ohman J, Salmi H. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology 2013; 124: 252–8.
27. Storey RF, James SK, Siegbahn A et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets.; 2013 Oct 15.
28. Scirica BM, Cannon CP, Emanuelsson H et al for the PLATO Investigators. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol 2011; 57: 1908–16.
29. DiNicolantonio JJ, Serebruany VL. Exploring the ticagrelor-statin interplay in the PLATO trial. Cardiology 2013; 124: 105–7.
30. Gurbel P.A., Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET Study. Circulation 2009; 120:
2577–85.
31. Bliden KP, Tantry US, Storey RF, et al. The effect of ticagrelor 
versus clopidogrel on high on-treatment platelet reactivity: 
Combined analysis of the ONSET/OFFSET and RESPOND studies. 
Am Heart J 2011; 162: 160–5.

О.Л.Барбараш, Е.В.Тавлуева

ФГБУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний СО РАМН, Кемерово